Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mass Drug Administration With Dihydroartemisinin-piperaquine and Primaquine to Reduce Malaria in a Moderate-low Transmission Setting in Senegal: A Cluster Randomized Controlled Trial

NCT04864444 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04864444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04864444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mass Drug Administration With Dihydroartemisinin-piperaquine and Primaquine to Reduce Malaria in a Moderate-low Transmission Setting in Senegal: A Cluster Randomized Controlled Trial
Lead sponsor
University of California, San Francisco
Phase
Not applicable
Overall status
Completed
Start date
June 19, 2021
Completion date
June 30, 2023
Enrollment
10,715 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, malaria,falciparum